Introduction: CGM can be used to monitor evolution of dysglycemia in presymptomatic, stage 2 type 1 diabetes (T1D) and to target early initiation of insulin upon reaching stage 3 T1D.

Methods: Participants (N=31) with dysglycemia by A1c, OGTT, CGM and/or home glucose testing (HGT) measures (Table 1) were randomized 2:1 into 6 months unblinded CGM-guided education intervention vs blinded CGM and monitoring only. Surveys included PHQ8, PedsQLFamilyImpact, Tolerance of Uncertainty and Diabetes Knowledge (30 point scale).

Results: Intervention and control group were similar in baseline characteristics (Table), except younger age and significantly higher 2-hour OGTT glucose level in the intervention group. Diabetes knowledge was not significantly different between intervention and control at baseline (22±6 vs 20±7, p=0.61) or 3-month follow-up (23±6 vs 20±4, p=0.28). There were no differences between groups for PHQ8, PedsQLFamilyImpact or Tolerance of Uncertainty at baseline or follow-up to date. Of those diagnosed with stage 3 T1D, CGM average sensor glucose and time >140 mg/dL were higher than at study entry. All participants met ADA stage 3 diagnostic criteria; however, none had A1c≥6.5%.

Conclusion: CGM facilitates early recognition of stage 3 T1D before elevation in HbA1c and metabolic decompensation. Unblinded CGM does not appear to negatively impact quality of life.


B.I.Frohnert: Advisory Panel; Provention Bio, Inc. F.Sepulveda: None. J.E.Stoughton: None. A.Steck: None. K.M.Simmons: Advisory Panel; Provention Bio, Inc., Consultant; Dexcom, Inc., Provention Bio, Inc., Research Support; Novartis.


The Leona M. and Harry B. Helmsley Charitable Trust (G-1911-03463)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at